Recombinant Human JAG1 Protein (C-Fc)

Name: Recombinant Human JAG1 Protein (C-Fc)
Brand: Beta LifeScience
SKU: BL-0040NP
Price: 368.0 USD
Availability: InStock

BL-0040NP: Greater than 90% as determined by reducing SDS-PAGE. (QC verified)

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Jagged-1 is produced by our Mammalian expression system and the target gene encoding Gln34-Ser1046 is expressed with a human IgG1 Fc tag at the C-terminus.
Accession	P78504
Synonym	Protein jagged-1 I; Jagged-1; JAGL1; HJ1; JAG1 and CD339
Gene Background	Protein jagged-1 I, also known as Jagged-1, JAGL1, HJ1, JAG1 and CD339, is a single-pass type I membrane protein. JAG1 contains one DSL domain and sixteen EGF-like domain. JAG1 acts as a ligand for multiple Notch receptors and is involved in the mediation of Notch signaling. JAG1 may participate in early and late stages of mammalian cardiovascular development, JAG1 inhibits myoblast differentiation and enhances fibroblast growth factor-induced angiogenesis. Defects in JAG1 are the cause of Alagille syndrome type 1, which is autosomal dominant multisystem disorder defined clinically by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations.
Molecular Mass	137.6 KDa
Apmol Mass	140-200 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 90% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Ligand for multiple Notch receptors and involved in the mediation of Notch signaling. May be involved in cell-fate decisions during hematopoiesis. Seems to be involved in early and late stages of mammalian cardiovascular development. Inhibits myoblast differentiation. Enhances fibroblast growth factor-induced angiogenesis (in vitro).
Subcellular Location	Membrane; Single-pass type I membrane protein.
Database References	HGNC: 6188 OMIM: 118450 KEGG: hsa:182 STRING: 9606.ENSP00000254958 UniGene: Hs.224012
Associated Diseases	Alagille syndrome 1 (ALGS1); Tetralogy of Fallot (TOF)
Tissue Specificity	Widely expressed in adult and fetal tissues. In cervix epithelium expressed in undifferentiated subcolumnar reserve cells and squamous metaplasia. Expression is up-regulated in cervical squamous cell carcinoma. Expressed in bone marrow cell line HS-27a wh

Gene Functions References

We observe similar stapes defects and hearing loss in one patient with heterozygous JAGGED1 loss, and a diversity of conductive and sensorineural hearing loss in nearly half of Alagille Syndrome patients, many of which carry JAGGED1 mutations PMID: 28566723
MFNG imposes a negative correlation between Jag1 and Notch, being high Jag1 in the absence of MFNG predictive of poor prognosis. PMID: 30065304
MiR-26b-5p acts as a tumor suppressor through suppressing cells proliferation and inducing cells apoptosis via directly targeting JAG1 in multiple myeloma PMID: 30098829
miR-30d may improve TGF-beta1-induced pulmonary fibrosis through direct binding to the 3'UTR of JAG1 and blocking JAG1/Notch signaling PMID: 30029934
these two lossoffunction JAG1 mutations may be associated with Alagille syndrome manifestations in these patients PMID: 29956768
Results provide evidence that JAG1 is downregulated by microRNA-128 binding its 3'UTR in glioma cells. PMID: 29091297
The demonstration that miR-124 inhibits gastric cancer cell growth supports the concept that miR-124 functions as a tumor suppressor by a mechanism that involves translational repression of the JAG1 and the inhibition of Notch signaling pathway. PMID: 28941308
The c.765C>T JAG1 variant is significantly associated with the pathogenesis of tetralogy of Fallot in the Iranian population. PMID: 29631691
Vascular smooth muscle cells were cyclically stretched on flexible membranes, as quantified via video tracking, demonstrating that the expression of Jagged1, Notch3, and target genes was down-regulated with strain. PMID: 29610298
This study identifies the unique role of JAG1-induced Notch activation in the pathogenesis of multiple myeloma PMID: 29242532
is an autosomal dominant disorder found to be linked to the Notch ligand JAG1.5 Approximately 90 percent of patients presenting with Alagille Syndrome have a mutation on the JAG1 gene that is located on chromosome 20p12. PMID: 29185945
These data indicate a process of NF-kappaB-induced miR-506 suppression and JAG1 upregulation upon IL-1beta induction. PMID: 28926924
In subjects with Alagille syndrome, incomplete clinical features of Alagille syndrome and biliary atresia, the frequency of mutations was as follows: single nucleotide variants (51.9%), small insertion or deletion (29.6%) and gross deletion (18.5%). PMID: 28695677
The Jagged1-Notch pathway showed elevated expression in AI-resistant breast cancer cells, resulting in macrophage differentiation towards M2 TAMs and there contributing to the acquisition of AI resistance. PMID: 28730338
Data show that Delta-like 4 (DLL4) and Jagged1 (JAG1) displayed equal potency in stimulating Notch target genes in HMEC-1 dermal microvascular endothelial cells but had opposing effects on sprouting angiogenesis in vitro. PMID: 28445154
Missense mutant of Jag1 (Jag1(Ndr)) disrupts bile duct development and is responsible for Alagille syndrome phenotypes in heart, eye, and craniofacial dysmorphology. PMID: 29162437
JAG1 was demonstrated to be a novel target of miR1405p, and miR1405p exerted its inhibitory effect on human glioma growth and invasion, partly by suppressing JAG1. PMID: 28713992
miR-141 may serve as an antioncomir in GSCs and markedly inhibit their self-renewal via downregulating Jagged1 expression levels in vitro and in vivo. PMID: 28535010
HIF1A potentiates Jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes. PMID: 28376567
the Notch signaling and atherosclerosis relevant markers in lesions from femoral arteries of symptomatic peripheral artery disease patients, were characterized. PMID: 28472949
Lower positive expression rate of RUNX3 and higher positive expression rate of Notch1 and Jagged 1 were observed in CRC tissues than those in normal adjacent tissues with a negative correlation, and the expression levels were associated with the differentiation degree, TNM staging, lymph node metastasis and tumor invasion depth (all P<0.05). PMID: 28498402
These findings imply that miR-199b-5p performs an inhibitory role in osteogenic differentiation in ligamentum flavum cells by potentially targeting JAG1 and influencing the Notch signalling pathway. PMID: 27957826
A three-molecule score based on the expression of Notch pathway molecules: Jagged1, intracellular Notch1 (ICN1) and Hes1 (JIH score) to assess prognostic value in non-metastasis clear cell renal cell carcinoma (ccRCC). PMID: 27612417
Jagged1 (JAG1) thymic medullary niche enriched for dendritic cells (DC)-lineage cells expressing Notch receptors indicate thymus as a DC-poietic organ, which provides selective microenvironments permissive for DC development. PMID: 28947612
Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with gallbladder cancers. PMID: 27174628
Data indicate that jagged 1 protein (JAG1)-mediated Notch signaling regulates differentiation of basal cells (BC) into secretory cells. PMID: 27216293
these results show that the Notch signaling pathway in T cells is crucial for the induction of TH2-mediated allergic airway inflammation in an house dust mite -driven asthma model but that expression of Jagged 1 or Jagged 2 on DCs is not required PMID: 28111308
Bruceine D inhibits hepatocellular carcinoma growth by targeting beta-catenin/jagged1 signaling pathways. PMID: 28645563
Results showed that JAG1 was significantly downregulated in miR-26a-overexpressing osteosarcoma cells and is a direct target of miR-26a. PMID: 27270422
the effects of two Notch ligands, i.e., Jagged1 and DLL1, on murine and human hematopoiesis in vitro. Our observations indicate that the stromal expression of Notch ligands increases the production of both the total and phenotypically early murine and human hematopoietic cells in the co-culture. PMID: 28537242
Specific Notch3 and Jag1 subcellular localization patterns may provide clues for the behavior of the corresponding tumors and could potentially be applied in the clinic for Jag1 targeting in triple-negative breast cancer patients. PMID: 28476798
there is a cross-talk between Jagged1/Notch3 and VEGF in TNBC angiogenesis. Jagged1/Notch3 is expected to be an important signaling pathway for TNBC progression and a potential target for TNBC neovascularization therapy. PMID: 28625320
Low levels of Notch pathway genes Notch1, Notch2, Notch4 and Jagged1 correlated with poor prognostic factors such as larger tumor size, positive lymph-node status, tumor phenotype and infiltrating tumor Treg cells. PMID: 27118257
Human Jagged-1 induced the proliferation and differentiation of CD133+ cord blood progenitors compared with hDll-1. Thus, hJagged-1 signaling in the bone marrow niche may be used to expand EPCs for therapeutic angiogenesis PMID: 27846321
By studying leprosy as a model, we provide evidence that upregulation of JAG1 on endothelium instructs monocytes to differentiate into M1 macrophages with antimicrobial activity. PMID: 27532668
High Jag1 expression is associated with metastasis in colorectal cancer. PMID: 28161537
amplification of Jagged1 contributed to mRNA expression that activates the Jagged1-Notch signaling pathway in liver cancer and led to poor outcome. PMID: 27315779
Our data revealed that MALAT1 inhibited tongue cancer cell growth and metastasis through miR-124-dependent JAG1 regulation. In conclusion, we revealed that MALAT1 may play an oncogenic role by increasing proliferation and metastasis of tongue cancer and is a potential therapeutic target in human tongue cancer. PMID: 28260102
Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with pancreatic ductal carcinoma. PMID: 27919854
miR-199a-3p targets YAP1, downregulates Jagged1 and suppresses the Notch signaling to inhibit hepatocellular carcinoma (HCC) cell proliferation and promote apoptosis. These findings provide new insights into the mechanism by which miR-199a-3p suppresses HCC cell proliferation and induces apoptosis. PMID: 27832779
Jagged1 activation of Notch3 resulted in a significant decrease in cell proliferation while concomitantly promoting Hemangioma-pericyte maturation. PMID: 27941324
expression of JAG1 is regulated by various pathways and is associated with poor prognosis through promoting the epithelial to mesenchymal transition and cell proliferation or maintaining cell survival in colorectal cancer PMID: 27589478
AGS is caused by mutations in one of two genes, namely, JAG1 or NOTCH2. These genes are part of the Notch signaling pathway, which is involved in cell fate determination. JAG1 mutations have been identified in 70-94% of individuals with clinically diagnosed AGS PMID: 25676721
On complete gene sequencing of JAG1 gene as described before, the patient was shown to be heterozygous for a known pathogenic mutationc.270delG (p.C92AfsX69) in exon 2 PMID: 25596152
JAG1 protein expression was significant positive correlation with lymph node metastasis, pathological grades invasive ductal carcinoma of breast.JAG1 gene methylation level in breast cancer. PMID: 26971121
these findings demonstrate that 50 microM EGCG protects against ox-LDL-induced endothelial dysfunction through the Jagged-1/Notch signaling pathway. PMID: 26648562
PKCalpha Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance PMID: 26350262
Immunohistochemical panel of CDX2, p120ctn, c-Myc, and Jagged1 proteins would be to distinguish between low/high grade dysplasia in histologically challenging cases of Barrett's esophagus. PMID: 26926447
High Jagged1 expression is associated with colorectal cancer. PMID: 26406415
High Jagged1 expression is associated with Prostatic Intraepithelial Neoplasia. PMID: 26341090

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.